当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
ELOCTATE, Antihemophilic Factor (Recombinant), Fc Fusion protein
申请企业
Bioverativ Therapeutics, Inc.
药品名称
ELOCTATE, Antihemophilic Factor (Recombinant), Fc Fusion protein
承诺描述
To complete trial 99HA306, An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A.